Business Wire

Russia’s largest cloud service provider deploys ADVA FSP 3000 to answer fierce data growth

11.9.2019 10:00:00 EEST | Business Wire | Press release

Share

ADVA (FSE: ADV) today announced that Inoventica has selected its FSP 3000 platform to meet soaring data demand from enterprise and carrier customers. Inoventica, one of Russia’s leading IT service providers and data center operators, will leverage the solution to boost the capacity of its backbone network to 100Gbit/s and beyond. The new fully redundant infrastructure leverages ADVA’s QuadFlex™ line card and OpenFabric™ cross-connect – two technologies optimized for efficiency and complete flexibility. ADVA’s Select partner, the IT solution specialist Zettaline is also playing a key role in facilitating the project.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190911005024/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The FSP 3000 platform enables Inoventica to meet soaring data demand from enterprise and carrier customers (Photo: Business Wire)

“ADVA’s technology enables us to take the next step with our infrastructure while also leveraging maximum value from our existing network. With this deployment, we can flexibly respond to soaring data requirements and help our customers to unleash their full potential,” said Vitaly Slizen, CEO, Inoventica. “The ADVA FSP 3000 delivers several key efficiencies from low latency to optimized bandwidth utilization. And the FSP 3000 OpenFabric™ empowers us to cost-effectively provide the data rates our customers need by aggregating 1Gbit/s and 10Gbit/s services onto 100Gbit/s wavelengths. Furthermore, its openness means we can reap the benefits of unlimited innovation cycles in the future.”

Designed for scalability and bandwidth optimization, the ADVA FSP 3000 ensures that Inoventica’s new infrastructure offers superb efficiency. It enables significant energy savings and, with its 1RU footprint, occupies very little rack space. Using ADVA FSP 3000 QuadFlex™ technology, the solution will transport 100Gbit/s data loads over distances stretching to 2,000km across the Moscow metropolitan area. By enabling greater spectral efficiency, QuadFlex™ delivers extended reach without any need for signal regeneration. Also key is the ADVA FSP 3000 OpenFabric™, which creates a distributed architecture, enabling Inoventica to simply and efficiently aggregate lower-speed services.

“We’re proud that Russia’s largest cloud service provider has chosen to harness our technology and expertise. Together with our partner Zettaline, we’ve built a solution that efficiently expands Inoventica’s infrastructure and provides the tools it needs to address today’s key challenges,” commented Andreas Jelinek, senior director, sales, Eastern Europe, Russia and CIS, ADVA. “The new fully redundant solution is protected, flexible and extremely cost-efficient. It also meets all of Inoventica’s density, security and energy requirements. Furthermore, thanks to the modular, scalable design of our FSP 3000 platform and the ongoing support of our team, Inoventica is free to plan an exciting roadmap for further development in the future.”

“This deployment is going to bring substantial benefits to a great number of Russian enterprises and we’re proud to be playing such a big part in helping Inoventica take this leap forward. Working closely with our friends at ADVA, we’ve created a transport system that squeezes maximum value from Inoventica’s existing resources while enabling the flexibility and capacity necessary for the 5G and IoT era,” said Alexander Hochmuth, shareholder representative, Zettaline Ltd. “As a team, ADVA and Zettaline provide both global knowledge and local expertise. Together, we’ve designed an open, disaggregated and completely future-proof solution that meets all of Inoventica’s needs and ambitions.”

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.advaoptical.com.

About Inoventica

INOVENTICA Group of Companies is the first Russian IT-operator that has been implementing projects based on innovative ICT Infrastructure of international scale based on cloud computing technologies since 1999. Partners and clients of the INOVENTICA Group of Companies are more than 5 thousand B2C subscribers, more than 1000 corporate clients (B2B), 48 national and international telecom operators. www.invs.ru

Published by:

ADVA Optical Networking SE, Munich, Germany
www.advaoptical.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For ADVA press:
Gareth Spence
t +44 1904 699 358
public-relations@advaoptical.com

For ADVA investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@advaoptical.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye